Abstract
1147
Objectives: Glucose management is vital to obtaining optimal results for not only Positron Emission Tomography (PET) scans with F-18 Flurodeoxyglucose (FDG), but also in Gastric Emptying. Moreover with the clinical appearance of additional metabolic tracers such as F-18 Fluciclovine and C-11 Choline, as well as other traditional tracer such as C-11 Methionine, etc. the need to properly prepare patients is important. Yet there is still a paucity of good clinical trials that have looked at how to optimally prepare patients. Additionally, many of the societal recommendations are based in the era when oral hypoglycemics and insulin were the mainstay of patient management. With the introduction of newer diabetic agents, Nuclear Medicine clinicians must have a working knowledge of how these agents should be handled when patients come for testing, but also understand the additional possibilities that open up in helping them better optimize patients for relevant studies.
Methods: This is an educational abstract which will review the newer classes of agents involved in the management of diabetes, their mechanism of action, and implications for performing studies in Nuclear Medicine.
Results: A review will be conducted to show the clinical evidence available for current recommendations in managing patients for Gastric Emptying, and those getting PET scans with metabolic tracers. Implications of how changing outpatient management techniques will impact performing Nuclear Medicine techniques will be discussed. Finally, some proposals will be suggested to alternate management techniques for the common difficulties Nuclear Medicine facilities face with patient preparation and clinical scenarios. Conclusion: Introduction of newer agents in the management of diabetes opens up not only newer challenges but also opportunities in optimizing patient preparation for Nuclear Medicine studies with PET using metabolic tracers, and Gastric Emptying. Some ideas are proposed to improve, or provide an alternate to current societal management guidelines. Future clinical trials are needed to further refine these ideas.
